Brendan Teehan sold $174k of ACAD
EVP, COO, HEAD OF COMMERCIAL at ACADIA PHARMACEUTICALS INC. 10,329 shares at an average of $16.81, traded Nov 19, 2024, filed Nov 19, 2024.
Score components
- +20RoleCOO
- +11Trade size$174k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +3.2%, 3m +21.8%, 6m +33.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027294, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2024 | MOption exercise Common Stock | +9,913 | - | - | 62,521 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Common Stock | +9,913 | - | - | 72,434 | Nov 19, 2024 |
| Nov 19, 2024 | SOpen-market sale Common Stock10b5-1 | -10,329 | $16.81 | $174k | 62,105 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitsderivative | -9,913 | $0.00 | $0 | 9,913 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitsderivative | -9,913 | $0.00 | $0 | 9,913 | Nov 19, 2024 |
Related signals
Other insiders at ACADIA PHARMACEUTICALS INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 14Weak | ACADIA PHARMACEUTICALS INC | Jennifer J Rhodes EVP, CHIEF LEGAL OFFICER, SEC | $83k 3,844 shares | -25% | |
| 1Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $42k 1,942 shares | -7% | |
| 28Weak | ACADIA PHARMACEUTICALS INC | Adams Catherine Owen Chief Executive Officer | $250k 11,641 shares | -44% | |
| 23Weak | ACADIA PHARMACEUTICALS INC | Elizabeth H.Z. Thompson EVP, Head of Research & Dev | $74k 3,435 shares | -51% | |
| 18Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $159k 7,385 shares | -12% | |
| 1Weak | ACADIA PHARMACEUTICALS INC | Jennifer J Rhodes EVP, CHIEF LEGAL OFFICER, SEC | $162k 6,950 shares | -48% | |
| 10Weak | ACADIA PHARMACEUTICALS INC | James Kihara PRINCIPAL ACCOUNTING OFFICER | $97k 4,084 shares | -14% | |
| 20Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $243k 10,262 shares | -16% | |
| 70Notable | ACADIA PHARMACEUTICALS INC | James M Daly director | $671k 30,000 shares | -88% | |
| 19Weak | ACADIA PHARMACEUTICALS INC | Mark C. Schneyer EVP, CHIEF FINANCIAL OFFICER | $83k 3,498 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.